1-16 of 16
Richard F. Kefford
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors

Jenny H. Lee, Alexander M. Menzies, Matteo S. Carlino, Ashleigh C. McEvoy, Shahneen Sandhu, Alison M. Weppler, Russell J. Diefenbach, Sarah-Jane Dawson, Richard F. Kefford, Michael J. Millward, Zeyad Al-Ogaili, Thien Tra, Elin S. Gray, Stephen Q. Wong, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 4064–4071.
https://doi.org/10.1158/1078-0432.CCR-19-3926
Published: 03 August 2020
View article titled, Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors
Open the PDF for Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy

Su Y. Lim, Jenny H. Lee, Tuba N. Gide, Alexander M. Menzies, Alexander Guminski, Matteo S. Carlino, Edmond J. Breen, Jean Y.H. Yang, Shila Ghazanfar, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long, Helen Rizos
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (5): 1557–1563.
https://doi.org/10.1158/1078-0432.CCR-18-2795
Published: 01 March 2019
View article titled, Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy
Open the PDF for Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma

Inês Pires da Silva, Kevin Y.X. Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John J. Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard F. Kefford, Helen Rizos, Richard A. Scolyer, Jean Y.H. Yang, Georgina V. Long, Alexander M. Menzies
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (4): 1272–1279.
https://doi.org/10.1158/1078-0432.CCR-18-1680
Published: 15 February 2019
View article titled, Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <em>BRAF</em>-Mutant Melanoma
Open the PDF for Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors

Hojabr Kakavand, Robert V. Rawson, Gulietta M. Pupo, Jean Y. H. Yang, Alexander M. Menzies, Matteo S. Carlino, Richard F. Kefford, Julie R. Howle, Robyn P.M. Saw, John F. Thompson, James S. Wilmott, Georgina V. Long, Richard A. Scolyer, Helen Rizos
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6054–6061.
https://doi.org/10.1158/1078-0432.CCR-16-1688
Published: 12 October 2017
View article titled, PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors
Open the PDF for PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

Jean-Pierre Delord, Caroline Robert, Marta Nyakas, Grant A. McArthur, Ragini Kudchakar, Amit Mahipal, Yasuhide Yamada, Ryan Sullivan, Ana Arance, Richard F. Kefford, Matteo S. Carlino, Manuel Hidalgo, Carlos Gomez-Roca, Daniela Michel, Abdelkader Seroutou, Vassilios Aslanis, Giordano Caponigro, Darrin D. Stuart, Laure Moutouh-de Parseval, Tim Demuth, Reinhard Dummer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5339–5348.
https://doi.org/10.1158/1078-0432.CCR-16-2923
Published: 15 September 2017
View article titled, Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma
Open the PDF for Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <em>BRAF</em>-Mutant Melanoma in another window
Includes: Supplementary data
Journal Articles

Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma

Ricardo E. Vilain, Alexander M. Menzies, James S. Wilmott, Hojabr Kakavand, Jason Madore, Alexander Guminski, Elizabeth Liniker, Benjamin Y. Kong, Adam J. Cooper, Julie R. Howle, Robyn P.M. Saw, Valerie Jakrot, Serigne Lo, John F. Thompson, Matteo S. Carlino, Richard F. Kefford, Georgina V. Long, Richard A. Scolyer
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5024–5033.
https://doi.org/10.1158/1078-0432.CCR-16-0698
Published: 31 August 2017
View article titled, Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Open the PDF for Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma in another window
Includes: Supplementary data
Journal Articles

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients

Hojabr Kakavand, James S. Wilmott, Alexander M. Menzies, Ricardo Vilain, Lauren E. Haydu, Jennifer H. Yearley, John F. Thompson, Richard F. Kefford, Peter Hersey, Georgina V. Long, Richard A. Scolyer
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (14): 3140–3148.
https://doi.org/10.1158/1078-0432.CCR-14-2023
Published: 14 July 2015
View article titled, PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients
Open the PDF for PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor–Treated Melanoma Patients in another window
Includes: Supplementary data
Journal Articles

Preexisting MEK1P124 Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients

Matteo S. Carlino, Carina Fung, Hamideh Shahheydari, Jason R. Todd, Suzanah C. Boyd, Mal Irvine, Adnan M. Nagrial, Richard A. Scolyer, Richard F. Kefford, Georgina V. Long, Helen Rizos
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 98–105.
https://doi.org/10.1158/1078-0432.CCR-14-0759
Published: 05 January 2015
View article titled, Preexisting MEK1<sup>P124</sup> Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients
Open the PDF for Preexisting MEK1<sup>P124</sup> Mutations Diminish Response to BRAF Inhibitors in Metastatic Melanoma Patients in another window
Includes: Supplementary data
Journal Articles

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, H.-Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna Pavlick, Melvin T. Chin, Steven J. O'Day, Samuel C. Blackman, C. Martin Curtis, Peter Lebowitz, Bo Ma, Daniele Ouellet, Richard F. Kefford
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4449–4458.
https://doi.org/10.1158/1078-0432.CCR-14-0887
Published: 01 September 2014
View article titled, Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)
Open the PDF for Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436) in another window
Includes: Supplementary data
Journal Articles

BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact

Helen Rizos, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Carina Fung, Jessica Hyman, Lauren E. Haydu, Branka Mijatov, Therese M. Becker, Suzanah C. Boyd, Julie Howle, Robyn Saw, John F. Thompson, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (7): 1965–1977.
https://doi.org/10.1158/1078-0432.CCR-13-3122
Published: 31 March 2014
View article titled, BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Open the PDF for BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact in another window
Includes: Supplementary data
Journal Articles

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

Alexander M. Menzies, Lauren E. Haydu, Lydia Visintin, Matteo S. Carlino, Julie R. Howle, John F. Thompson, Richard F. Kefford, Richard A. Scolyer, Georgina V. Long
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3242–3249.
https://doi.org/10.1158/1078-0432.CCR-12-0052
Published: 14 June 2012
View article titled, Distinguishing Clinicopathologic Features of Patients with V600E and V600K <em>BRAF</em>-Mutant Metastatic Melanoma
Open the PDF for Distinguishing Clinicopathologic Features of Patients with V600E and V600K <em>BRAF</em>-Mutant Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

James S. Wilmott, Georgina V. Long, Julie R. Howle, Lauren E. Haydu, Raghwa N. Sharma, John F. Thompson, Richard F. Kefford, Peter Hersey, Richard A. Scolyer
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (5): 1386–1394.
https://doi.org/10.1158/1078-0432.CCR-11-2479
Published: 01 March 2012
View article titled, Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Open the PDF for Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial

Ian D. Davis, Ben Brady, Richard F. Kefford, Michael Millward, Jonathan Cebon, Birte K. Skrumsager, Ulrik Mouritzen, Lasse Tengbjerg Hansen, Kresten Skak, Dorthe Lundsgaard, Klaus Stensgaard Frederiksen, Paul E.G. Kristjansen, Grant McArthur
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (6): 2123–2129.
https://doi.org/10.1158/1078-0432.CCR-08-2663
Published: 16 March 2009
View article titled, Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial
Open the PDF for Clinical and Biological Efficacy of Recombinant Human Interleukin-21 in Patients with Stage IV Malignant Melanoma without Prior Treatment: A Phase IIa Trial in another window
Includes: Supplementary data
Journal Articles

Frequent Loss of Heterozygosity Targeting the Inactive X Chromosome in Melanoma

James O. Indsto, Najah T. Nassif, Richard F. Kefford, Graham J. Mann
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (17): 6476–6482.
Published: 24 December 2003
View article titled, Frequent Loss of Heterozygosity Targeting the Inactive X Chromosome in Melanoma
Open the PDF for Frequent Loss of Heterozygosity Targeting the Inactive X Chromosome in Melanoma in another window
Journal Articles

X Inactivation, DNA Deletion, and Microsatellite Instability in Common Acquired Melanocytic Nevi

James O. Indsto, Adrian R. Cachia, Richard F. Kefford, Graham J. Mann
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (12): 4054–4059.
Published: 01 December 2001
View article titled, X Inactivation, DNA Deletion, and Microsatellite Instability in Common Acquired Melanocytic Nevi
Open the PDF for X Inactivation, DNA Deletion, and Microsatellite Instability in Common Acquired Melanocytic Nevi in another window
Journal Articles

Functional Impairment of Melanoma-associated p16INK4a Mutants in Melanoma Cells despite Retention of Cyclin-dependent Kinase 4 Binding

Therese M. Becker, Helen Rizos, Richard F. Kefford, Graham J. Mann
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (10): 3282–3288.
Published: 01 October 2001
View article titled, Functional Impairment of Melanoma-associated p16<sup>INK4a</sup> Mutants in Melanoma Cells despite Retention of Cyclin-dependent Kinase 4 Binding
Open the PDF for Functional Impairment of Melanoma-associated p16<sup>INK4a</sup> Mutants in Melanoma Cells despite Retention of Cyclin-dependent Kinase 4 Binding in another window